source
- Sanofi’s new CEO vows deeper review of late-stage pipeline after series of trial failuresSanofi appointed Belén Garijo as chief executive in February with a clear mandate to tighten R&D governance and boost productivity. The board tasked her with bringing more rigor to the company’s st…
- Merck briefly lists, then removes, phase 2 trial of PD-1xVEGF bispecific with TROP2 ADCMerck & Co. posted a clinical trial listing for a phase‑2 study combining its PD‑1xVEGF bispecific antibody (MK‑2010) with the TROP2‑directed antibody‑drug conjugate sac‑TMT. The listing, shown as…